Deep Insight into the Role of MIF in Spondyloarthritis

Area of Science:

• Immunology
• Rheumatology
• Molecular Biology

Background:

• Macrophage migration inhibitory factor (MIF) has emerged as a significant factor in spondyloarthritis (SpA) pathogenesis.
• Preclinical models indicate MIF's pathological role in SpA, positioning it as a potential therapeutic target.
• The precise contribution of MIF to different tissues affected by SpA and the efficacy of targeted therapies require further clarification.

Purpose of the Study:

• To review the pathological roles of MIF in spondyloarthritis (SpA).
• To delineate the specific contribution of MIF to various tissue types affected by SpA.
• To evaluate the therapeutic potential of MIF-targeted therapies for SpA.

Main Methods:

• Review of preclinical models demonstrating MIF's role in SpA.
• Analysis of studies investigating MIF and its receptor CD74 in SpA pathogenesis.
• Examination of clinical trial data for MIF- or CD74-targeted therapies in other diseases.

Main Results:

• MIF and its receptor CD74 are implicated in the pathogenesis of SpA affecting the spine, joints, eyes, skin, and gut.
• Evidence consistently shows MIF drives inflammation in these distinct anatomical sites.
• Genetic deletion or blockade of MIF reduces inflammation severity in preclinical SpA models.
• MIF promotes type 3 immunity by enhancing T helper 17 (Th17) plasticity.
• MIF- or CD74-targeted therapies have shown good tolerability in clinical trials for other conditions.

Conclusions:

• The MIF-CD74 axis represents a novel therapeutic target for SpA.
• Targeting MIF-CD74 may improve various clinical features of SpA.
• Clinical trials investigating MIF- or CD74-targeted therapies in SpA patients are necessary.